Disease:
Depressive Disorder, Major

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No VIP available CYP2C19 *1 N/A N/A N/A
No VIP available CA No VIP available CYP2C19 *2 N/A N/A N/A
No VIP available CA No VIP available CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C19 *4 N/A N/A N/A
No VIP available CA No VIP available CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *3 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *1 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *1XN N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *2 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *2XN N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *3 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *4 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *5 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *6 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2D6 *9 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2D6 *17 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2D6 *39 N/A N/A N/A
No VIP available CA No VIP available CYP2D6 *41 N/A N/A N/A
No VIP available CA No VIP available SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available CA No VIP available SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No VIP available No VIP available SLC6A4 L allele-rs25531C N/A N/A N/A
No VIP available No VIP available No VIP available SLC6A4 L allele-rs25531T N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 poor metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 ultrarapid metabolizer phenotype N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10008257 19904049G>A, 95356328G>A
G > A
Not Available
No VIP available CA VA
rs10036156 15026911T>C, 170215638T>C, 19T>C, Leu7=
T > C
Synonymous
Leu7Leu
No VIP available CA VA
rs10042486 13855688C>T, 1791G>A, 63261329C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1006737 2285295G>A, 2345295G>A, 270344G>A, 477+115699G>A
G > A
Intronic
No VIP available CA VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs1062613 -24T>C, 113846006T>C, 17408422T>C, 210T>C, 5210T>C, HTR3A:C178T, Pro16Ser
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs1065852 100C>T, 21917263G>A, 42526694G>A, 5190C>T, CYP2D6:100C>T, Pro34Ser, part of CYP2D6*4 and CYP2D6*10
G > A
Missense
Pro34Ser
No VIP available No Clinical Annotations available VA
rs1074145 47486310G>A, 96681846G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs10848635 2256195T>A, 2316195T>A, 241244T>A, 477+86599T>A
T > A
Intronic
No VIP available CA VA
rs10879346 24210C>T, 34495141C>T, 608+8400C>T, 72351835C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs10975641 2053-537G>C, 6546839C>G, 6556839C>G, 93854G>C
C > G
Intronic
No VIP available No Clinical Annotations available VA
rs110402 -498-4332G>A, -498-4332G>C, -498-4332G>T, 23410A>A, 23410A>C, 23410A>T, 34-4338G>A, 34-4338G>C, 34-4338G>T, 43880047G>A, 43880047G>C, 43880047G>T, 9154199G>A, 9154199G>C, 9154199G>T, 987481C>A, 987481C>G, 987481C>T
C > T
Intronic
No VIP available CA VA
rs11042725 -1473C>A, -1923, 10265325C>A, 10325325C>A, ADM:, C>A
C > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs1109866 117G>A, 220083279C>T, 5434G>A, 70292697C>T, Leu39=
C > T
Synonymous
Leu39Leu
No VIP available No Clinical Annotations available VA
rs1109867 -58C>A, 220083453G>T, 5260C>A, 70292871G>T
G > T
5' UTR
No VIP available No Clinical Annotations available VA
rs11144870 235-641G>A, 79004213C>T, 8168745C>T
C > T
Intronic
No VIP available CA No Variant Annotations available
rs11188072 -3402, 1599C>T, 47323525C>T, 96519061C>T, CYP2C19:, CYP2C19: -3402C>T, part of CYP2C19*17
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs11195419 *216C>A, 112839368C>A, 63643832C>A, 7579C>A
C > A
3' UTR
No VIP available No Clinical Annotations available VA
rs1128503 1236T>C, 167964T>C, 25043506A>G, 87550285A>G, ABCB1 1236C>T, ABCB1*8, ABCB1: c.1236T>C, ABCB1:1236C>T, ABCB1:1236T>C, Gly412=, Gly412Gly, mRNA 1654T>C, p.Gly412Gly
A > G
Not Available
Gly412Gly
No VIP available No Clinical Annotations available VA
rs1160351 280+127738T>G, 29015982A>C, 48015982A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs11628713 1546+49C>T, 54721775C>T, 73721775C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs1176744 113803028A>C, 17365444A>C, 32440A>C, 386A>C, Tyr129Ser
A > C
Missense
Tyr129Ser
No VIP available No Clinical Annotations available VA
rs12054895 27601431G>T, 27611431G>T
G > T
Not Available
No VIP available CA No Variant Annotations available
rs12248560 -806C>A, -806C>T, 4195C>A, 4195C>T, 47326121C>A, 47326121C>T, 96521657C>A, 96521657C>T, CYP2C19*17, CYP2C19*17 CYP2C19: -806C>T, CYP2C19: -806C>T
C > T
C > A
5' Flanking
No VIP available CA VA
rs13306278 -485C>T, 103+197G>A, 19929027C>T, 3081177C>T, 4765C>T, 5333G>A
C > T
Intronic
No VIP available CA VA
rs13432159 46795774T>G, 67973887T>G
T > G
Not Available
No VIP available No Clinical Annotations available VA
rs13515 *2653G>A, 111085G>A, 1506455C>T, 22115886C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs1360780 106-2636A>G, 35547571T>C, 35607571T>C, 93790A>G
T > C
Intronic
No VIP available CA VA
rs1364043 13845210T>G, 63250851T>G
T > G
Not Available
No VIP available No Clinical Annotations available VA
rs1374385 -1099G>C, 239149645C>G, 5095904C>G
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs1386494 24918T>C, 34495849T>C, 608+9108T>C, 72352543T>C
T > C
Intronic
No VIP available CA VA
rs153549 112236297A>G, 20550169A>G, 351+1780T>C
A > G
Intronic
No VIP available CA VA
rs153560 112254377G>A, 20568249G>A, 212+2483C>T
G > A
Intronic
No VIP available CA VA
rs16965962 105807023C>A, 18896699C>A
C > A
Not Available
No VIP available CA VA
rs17135437 101115994C>T, 379+24926C>T, 39148837C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs17244587 *303G>A, 11097187G>A, 17426G>A, 45823035G>A
G > A
3' UTR
No VIP available CA VA
rs1799889 -817_-816insA, -817_-816insG, 100769710_100769711insA, 100769710_100769711insG, 38802553_38802554insA, 38802553_38802554insG, 4332_4333insA, 4332_4333insG
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs1800042 13851088C>T, 63256729C>T, 6391G>A, 818G>A, Gly273Asp
C > T
Missense
Gly273Asp
No VIP available CA VA
rs1800532 17987816G>T, 18047816G>T, 19520C>A, 803+221C>A
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs1801252 115804036A>G, 145A>G, 5231A>G, 66608500A>G, ADRB1:49Ser>Gly, ADRB1:Ser49Gly, Ser49Gly
A > G
Missense
Ser49Gly
No VIP available No Clinical Annotations available VA
rs1801253 115805056G>C, 1165C>G, 1165G>C, 6251G>C, 66609520G>C, ADRB1:389Arg>Gly, ADRB1:Arg389Gly, Gly389Arg
G > C
Missense
Gly389Arg
No VIP available No Clinical Annotations available VA
rs1805054 19992513C>T, 267C>T, 6672601C>T, Tyr89=
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs182694 43698815A>G, 522+1760A>G, 579+1760A>G, 588+1760A>G, 594+1760A>G, 621+1760A>G, 693256A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs1928040 28427236G>A, 28934C>T, 361+19289C>T, 47447236G>A, 613+19289C>T
G > A
Intronic
No VIP available CA VA
rs1954787 120663363T>C, 24225779T>C, 83-10039T>C
T > C
Intronic
No VIP available CA VA
rs1969624 32+3829T>C, 45674818T>C, 45734818T>C
T > C
Intronic
No VIP available CA VA
rs1992647 -1822G>A, 161111174G>A, 5922447G>A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs201522 101771546G>A, 317363G>A, 39804389G>A, 52596G>A, 569+12993G>A, 596+12993G>A, 659+12993G>A, 674+12993G>A, 707+12993G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > T
A > C
Missense
Ser893Ala
Ser893Thr
No VIP available CA VA
rs2032583 187004T>C, 25193404A>G, 2685+49T>C, 87160561A>G
A > G
Intronic
No VIP available CA VA
rs2069521 29085G>A, 3113A>G, 45829524G>A, 75038967G>A, CYP1A2:
G > A
Not Available
No VIP available CA VA
rs2069526 -10+103T>G, 31459T>G, 45831898T>G, 739T>G, 740T>G, 75041341T>G, CYP1A2*1E
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs2216711 124+5982C>T, 151+5904C>T, 15939C>T, 202+5904C>T, 37818844G>A, 37828844G>A, 73+5982C>T
G > A
Intronic
No VIP available CA VA
rs2227631 -989A>G, 100769538A>G, 38802381A>G, 4160A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2227684 100776931G>A, 11553G>A, 38809774G>A, 656-45G>A, 701-45G>A
G > A
Intronic
No VIP available CA VA
rs2228478 -2205A>G, 1547225A>G, 3192A>G, 7322A>G, 89986608A>G, 942A>G, Thr314=
A > G
5' Flanking
Thr314Thr
No VIP available CA VA
rs2228479 1546557G>A, 2524G>A, 274G>A, 6654G>A, 89985940G>A, Val92Met
G > A
Missense
Val92Met
No VIP available CA No Variant Annotations available
rs2235015 148001G>T, 25232407C>A, 287-25G>T, 87199564C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs2235040 181815G>A, 2481+24G>A, 25198593C>T, 87165750C>T
C > T
Intronic
No VIP available CA No Variant Annotations available
rs2235067 197643G>A, 25182765C>T, 2786+170G>A, 87149922C>T
C > T
Intronic
No VIP available CA VA
rs2245705 334-1268T>C, 45689722T>C, 45749722T>C
T > C
Intronic
No VIP available CA VA
rs2251954 -1410A>G, 32+795T>C, 45671784T>C, 45731784T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs2254237 19975859C>T, 20035859C>T, 2577-21646C>T, 2769-21646C>T, 2838-21646C>T, 668589C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2270007 30689972G>C, 30699972G>C, 44748C>G, 789+217C>G, 828+217C>G, 831+217C>G, 912+217C>G
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs2296840 -17C>T, 151372047C>T, 2860689C>T
C > T
5' UTR
No VIP available CA No Variant Annotations available
rs242941 -404-1310A>C, -404-1310A>G, -404-1310A>T, 122-1310A>C, 122-1310A>G, 122-1310A>T, 122-6202A>C, 122-6202A>G, 122-6202A>T, 35892C>C, 35892C>G, 35892C>T, 43892520A>C, 43892520A>G, 43892520A>T, 9166672A>C, 9166672A>G, 9166672A>T, 975003G>A, 975003G>C, 975003G>G, CRHR1:rs242941
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs2433320 19918526G>A, 95370805G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs2452600 -266+2338C>T, 20044603C>T, 291+2338C>T, 292-212C>T, 407C>T, 41C>T, 95496882C>T, Ser136Phe, Ser14Phe
C > T
Intronic
Ser14Phe
No VIP available CA VA
rs2470890 +, 1548C>T, 295T>C, 37544C>T, 45837983C>T, 75047426C>T, Asn516=, CYP1A2*1B, CYP1A2:1545T>C, CYP1A2:1548T>C, CYP1A2:5347T>C, CYP1A2:Asn516Asn, CYP1A2:Ex7
C > T
Synonymous
Asn516Asn
No VIP available CA VA
rs2472304 1042+43G>A, 34356G>A, 45834795G>A, 75044238G>A
G > A
Intronic
No VIP available CA VA
rs2500535 149329267A>G, 53498724A>G, 682-11008A>G
A > G
Intronic
No VIP available CA VA
rs25531 -1936A>G, 28564346T>C, 3301340T>C, 3609A>G
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs2734833 113292920G>A, 16855336G>A, 285+2169C>T, 58082C>T
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs2740574 -392G>A, 37414939C>T, 4713G>A, 5'-flanking region -392A>G, 99382096C>T, CYP3A4*1B, CYP3A4-V, CYP3A4:-392A>G
C > T
5' Flanking
No VIP available CA VA
rs2742390 45696722G>A, 45756722G>A, 577+1151G>A
G > A
Intronic
No VIP available CA VA
rs2742417 -1077G>A, 32+462C>T, 45671451C>T, 45731451C>T
C > T
Intronic
No VIP available CA VA
rs2742421 32+1526T>G, 45672515T>G, 45732515T>G
T > G
Intronic
No VIP available CA VA
rs2742423 32+2441A>G, 45673430A>G, 45733430A>G
A > G
Intronic
No VIP available CA VA
rs2742435 33-4067G>A, 45680863G>A, 45740863G>A
G > A
Intronic
No VIP available CA VA
rs28401781 199237G>A, 25181171C>T, 2927+314G>A, 87148328C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2973049 125-1902A>G, 152-1902A>G, 203-1902A>G, 26644A>G, 37808139T>C, 37818139T>C, 74-1902A>G
T > C
Intronic
No VIP available CA VA
rs334558 -1001T>C, -1195A>G, 119813282A>G, 26308428A>G, 4983T>C, GSK3B: -50 T>C
A > G
5' Flanking
No VIP available CA VA
rs352428 16337038A>G, 28478892A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs363343 119014948C>A, 69819412C>A, 791-42C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs363371 118986396G>A, 69790860G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs363390 119004079G>C, 464+255G>C, 69808543G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs365836 101809851A>G, 355668A>G, 39842694A>G, 619-3875A>G, 646-3875A>G, 709-3875A>G, 724-3875A>G, 757-3875A>G, 90901A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs3731885 *700C>T, -1074C>T, 220084469G>A, 4244C>T, 70293887G>A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs3743484 1043-65G>C, 34518G>C, 45834957G>C, 75044400G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs3747802 -440T>C, 25375429A>G, 458+2615A>G, 4979T>C, 509+2615A>G, 87342586A>G
A > G
5' UTR
No VIP available No Clinical Annotations available VA
rs3755047 *305C>T, -1469C>T, 220084864G>A, 3849C>T, 70294282G>A
G > A
5' Flanking
No VIP available CA VA
rs3761554 -1145T>C, 122317244T>C, 4149T>C, 6584954T>C
T > C
5' Flanking
No VIP available CA VA
rs3761555 -1952T>C, 122316437T>C, 3342T>C, 6584147T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs3800373 *1136G>T, 158885G>T, 35482476C>A, 35542476C>A
C > A
3' UTR
No VIP available CA VA
rs3810651 1432T>A, 151821277T>A, 19641T>A, 2739215T>A, Phe478Ile
A > T
Missense
Phe478Ile
No VIP available No Clinical Annotations available VA
rs3813929 -759, -759C>T, -850C>T, 113818520C>T, 250852C>T, 4970C>T, HTR2C:, HTR2C: -759C/T
C > T
5' Flanking
No VIP available CA VA
rs3892097 21915516C>T, 353-1G>A, 42524947C>T, 506-1G>A, 6937G>A, CYP2D6*4, CYP2D6:1846G>A, part of CYP2D6*4
C > T
Acceptor
No VIP available CA VA
rs41271330 55579028G>A, 55639028G>A, 846C>T, Asn282=
G > A
Synonymous
Asn282Asn
No VIP available CA VA
rs4148739 186516A>G, 2482-236A>G, 25193892T>C, 87161049T>C
T > C
Intronic
No VIP available CA No Variant Annotations available
rs4148740 195462T>C, 25184946A>G, 2686-1911T>C, 87152103A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4244285 24154G>A, 24154G>C, 47346080G>A, 47346080G>C, 681G>A, 681G>C, 96541616G>A, 96541616G>C, CYP2C19*2, CYP2C19:681G>A, CYP2C19:G681A, Pro227=
G > A
G > C
Synonymous
Pro227Pro
No VIP available No Clinical Annotations available VA
rs4460839 -32+24002G>A, -986G>A, 113321796C>T, 16884212C>T, 29206G>A
C > T
5' Flanking
No VIP available CA VA
rs4646425 33399C>T, 45833838C>T, 75043281C>T, 832-249C>T
C > T
Intronic
No VIP available CA VA
rs4646427 1253+81T>C, 35810T>C, 45836249T>C, 75045692T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs4675690 208507807C>T, 58717225C>T
C > T
Not Available
No VIP available CA VA
rs4680 1-5G>A, 19951271G>A, 27009G>A, 3103421G>A, 322G>A, 472G>A, COMP: Val158Met, COMT:Val108Met, Val108Met, Val158Met
G > A
5' Flanking
Val158Met
No VIP available CA VA
rs4713916 -20+18122T>C, 31378T>C, 35609983A>G, 35669983A>G
A > G
Intronic
No VIP available CA VA
rs495794 112201094A>G, 20514966A>G, 225+665A>G, 229+665A>G, 301+665A>G
A > G
Intronic
No VIP available CA VA
rs502434 1200T>C, 122537277T>C, 224183T>C, 6804987T>C, Asn400=
T > C
Synonymous
Asn400Asn
No VIP available CA VA
rs5030655 -1098delA, -1563delA, -951delA, -988delA, 23419520delA, 277delT, 353-140delT, 40+3506delA, 42129084delA, 454delT, 51411delA, 51425delA, 5908delT, CYP2D6*6, CYP2D6:1707 del T, Trp152Glyfs, Trp93Glyfs, part of CYP2D6*6
A > -
Not Available
Trp152Gly
No VIP available No Clinical Annotations available VA
rs518147 -697G>C, -788G>C, 113818582G>C, 250914G>C, 5032G>C, HTR2C: -697G/C
C > G
5' UTR
No VIP available CA VA
rs5443 10501C>T, 47295C>T, 6894875C>T, 6954875C>T, 825C>T, GNB3:825C>T, GNB3:Ser275Ser, Ser275=
C > T
Synonymous
Ser275Ser
No VIP available No Clinical Annotations available VA
rs5569 1287G>A, 47294G>A, 55731835G>A, 9346034G>A, 972G>A, Thr324=, Thr429=
G > A
Synonymous
Thr429Thr
No VIP available No Clinical Annotations available VA
rs56294817 -424G>T, 239148970C>A, 5095229C>A
C > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs57098334 GGGTGGGCT, SLC6A4:
C > (CCCACCCGA)12
C > (CCCACCCGA)9
C > (CCCACCCGA)10
Not Available
No VIP available No Clinical Annotations available VA
rs6127921 25834842A>C, 55638750A>C
A > C
Not Available
No VIP available CA VA
rs61888800 -1325C>A, -22+18780C>A, -22+19615C>A, -22+19698C>A, -22+19913C>A, -22+250C>A, -22+566C>A, -422+240C>A, -571C>A, -589C>A, -59+240C>A, -696C>A, -77C>A, 26328C>A, 27662278G>T, 27722278G>T, 3+20681C>A, 66+240C>A
G > T
Intronic
No VIP available CA VA
rs6265 196G>A, 220G>A, 241G>A, 27619916C>T, 27679916C>T, 283G>A, 434C>T, 442G>A, 503C>T, 68690G>A, BDNF:Val66Met, Val148Met, Val66Met, Val74Met, Val81Met, Val95Met
C > T
Missense
Val66Met
No VIP available CA VA
rs6280 113890815C>T, 12085G>A, 20385961C>T, 25G>A, DRD3 Ser9Gly, DRD3 rs6280, DRD3: 9 Ser>Gly, DRD3: Gly9Ser, DRD3: Ser9Gly, DRD3:Ser9Gly, Gly9Ser, c.25T>C, p.S9G
C > T
Missense
Gly9Ser
No VIP available CA VA
rs6295 1-1019C>G, 1-1019G>C, 13852924C>C, 13852924C>G, 4555G>C, 4555G>G, 63258565C>C, 63258565C>G, HTR1A: -1019C/G
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs6311 -1438, -510G>A, -998G>A, 28451478C>T, 4692G>A, 47471478C>T, G>A, HTR2A c.-1438G>A, HTR2A:, HTR2A: -1438G/A, HTR2A:-1438G>A
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
No VIP available CA VA
rs6314 1102C>T, 1354C>T, 28389034G>A, 47409034G>A, 67136C>T, HTR2A: C1354T, HTR2A: His452Tyr, His368Tyr, His452Tyr
G > A
Missense
His368Tyr
No VIP available No Clinical Annotations available VA
rs6318 113965735G>C, 152185G>C, 398067G>C, 68G>C, Cys23Ser, HTR2C:23Ser, HTR2C:Cys23Ser
C > G
Missense
Cys23Ser
No VIP available No Clinical Annotations available VA
rs6740584 208429351T>C, 262-2836T>C, 304-2836T>C, 39736T>C, 58638769T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs6928 *3535G>C, 111967G>C, 1505573C>G, 22115004C>G
C > G
3' UTR
No VIP available No Clinical Annotations available VA
rs6946119 25161708T>C, 87128865T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs6966038 156880398A>G, 2509764A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs7103411 -128-19652G>A, -21-19993G>A, -421-4236G>A, -58-4236G>A, 1307+1439C>T, 25-19993G>A, 27640125C>T, 27700125C>T, 4-19993G>A, 48481G>A, 586-18900C>T, 67-19993G>A, 743+1439C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs7124442 *2326A>A, 27617041C>T, 27677041C>T, 306-2747C>T, 375-2747C>T, 71564A>A
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs7242 *722T>G, 100781445T>G, 16067T>G, 38814288T>G
T > G
3' UTR
No VIP available No Clinical Annotations available VA
rs7569963 208473184G>A, 58682602G>A
G > A
Not Available
No VIP available CA VA
rs762551 -9-154C>A, 32035C>A, 45832474C>A, 75041917C>A, CYP1A2*1F, CYP1A2:734C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
No VIP available No Clinical Annotations available VA
rs7997012 28391985A>G, 362-2211T>C, 47411985A>G, 5-HTR2A intron 2 variant, 614-2211T>C, 64185T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs809736 166+191464T>C, 196715T>C, 32120345A>G, 61329788A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs8136867 119+16819C>T, 1595362G>A, 22178C>T, 22204793G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs889895 -9+4071A>G, 208398929A>G, 58608347A>G, 9314A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs915120 121190113T>C, 597+163T>C, 71994577T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs9282564 118125A>G, 25262283T>C, 61A>G, 87229440T>C, ABCB1: c.61A>G, Asn21Asp, mRNA 479A>G, p.Asn21Asp
T > C
Missense
Asn21Asp
No VIP available No Clinical Annotations available VA
rs929493 119019126C>T, 69823590C>T, 991+1723C>T
C > T
Intronic
No VIP available CA VA
rs9380524 112291G>T, 251-1019G>T, 35529070C>A, 35589070C>A
C > A
Intronic
No VIP available CA VA
rs948854 -1998C>T, 13755998C>T, 68450203C>T
C > T
5' Flanking
No VIP available CA VA
rs962369 -22+6638A>C, -22+6638A>G, -22+6638A>T, -22+7473A>C, -22+7473A>G, -22+7473A>T, -22+7556A>C, -22+7556A>G, -22+7556A>T, -22+7771A>C, -22+7771A>G, -22+7771A>T, 14186A>C, 14186A>G, 14186A>T, 27674420T>A, 27674420T>C, 27674420T>G, 27734420T>A, 27734420T>C, 27734420T>G, 3+8539A>C, 3+8539A>G, 3+8539A>T
T > C
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names: 
Synonym
Major depression; Major depressive disorder; major depression
PharmGKB Accession Id: PA447321
External Vocabularies

Curated Information ?

Curated Information ?

No related diseases are available

Publications related to Depressive Disorder, Major: 282

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a chinese population. Therapeutic drug monitoring. 2014. Wang Xin-Chen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. European journal of clinical pharmacology. 2014. Waade Ragnhild Birkeland, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. Pharmacogenomics. 2014. Kawaguchi Daniel M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014. Zai Gwyneth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Treatment Outcomes of Depression: The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study. Journal of clinical psychopharmacology. 2014. Mrazek David A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations: Genome-Wide Associations. British journal of clinical pharmacology. 2014. Ji Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. Pharmacogenomics and personalized medicine. 2014. Saruwatari Junji, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of psychopharmacology (Oxford, England). 2013. Hodgson Karen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013. Huang Xiaoye, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. Journal of psychopharmacology (Oxford, England). 2013. Tammiste Anu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Human psychopharmacology. 2013. Ng Chee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. European archives of psychiatry and clinical neuroscience. 2013. Musil Richard, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Dynamics and persistence of CYP2D6 inhibition by paroxetine. Journal of clinical pharmacy and therapeutics. 2013. Juřica J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. Journal of clinical pharmacy and therapeutics. 2013. Chen B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature genetics. 2013. Cross-Disorder Group of the Psychiatric Genomics Consortium, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLC6A4 Polymorphisms and Age of Onset in Late-life Depression on Treatment Outcomes with Citalopram: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2013. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics. 2013. Kuo Hsiang-Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Progress in neuro-psychopharmacology & biological psychiatry. 2013. Calati Raffaella, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenetics and genomics. 2013. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics in major depression: a comprehensive meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2013. Niitsu Tomihisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder. Psychiatry research. 2013. Hopkins Seth C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A mega-analysis of genome-wide association studies for major depressive disorder. Molecular psychiatry. 2013. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. The pharmacogenomics journal. 2013. Brandl E J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. Journal of child and adolescent psychopharmacology. 2013. Rotberg Benyamin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease. Alimentary pharmacology & therapeutics. 2013. Ananthakrishnan A N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. Journal of clinical psychopharmacology. 2013. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics. 2013. Pu Mengjia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. The American journal of psychiatry. 2013. GENDEP Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clinical pharmacology and therapeutics. 2013. Hicks J K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Molecular psychiatry. 2013. Peñas-Lledó E M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenetics and genomics. 2013. Ellsworth Katarzyna A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology. 2013. Myung Woojae, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders. International journal of clinical and experimental medicine. 2013. Liu Zhongchun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology. 2013. Arias Bárbara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment. Psychiatry research. 2012. Wang Yingcheng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. Journal of clinical psychopharmacology. 2012. Tsuchimine Shoko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population. General hospital psychiatry. 2012. Yang Zhenxing, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry research. 2012. Kurose Kouichi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. The pharmacogenomics journal. 2012. Ji Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics. 2012. Oved Keren, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychological medicine. 2012. Clark S L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. The pharmacogenomics journal. 2012. de Klerk O L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. The pharmacogenomics journal. 2012. Sasayama D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of psychopharmacology (Oxford, England). 2012. Huezo-Diaz Patricia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. Journal of affective disorders. 2012. Mushtaq Dhuha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. The pharmacogenomics journal. 2012. Perlis R H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. European journal of clinical pharmacology. 2011. Ishiguro Shin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mitochondrial mutations and polymorphisms in psychiatric disorders. Frontiers in genetics. 2012. Sequeira Adolfo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology. 2012. Won Eun-Soo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS medicine. 2012. Tansey Katherine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response. PloS one. 2012. McCarthy Michael J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Translational psychiatry. 2012. Adkins D E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2011. Strohmaier Jana, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2011. Smith Jennifer Cohen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neuroscience letters. 2011. Viikki Merja, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility. Clinical pharmacology and therapeutics. 2011. Dobrinas M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. Journal of psychopharmacology (Oxford, England). 2011. Suzuki Yutaro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of psychopharmacology (Oxford, England). 2011. Keers Robert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide linkage analysis of 972 bipolar pedigrees using single-nucleotide polymorphisms. Molecular psychiatry. 2011. Badner J A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Progress in neuro-psychopharmacology & biological psychiatry. 2011. Yoshimura Reiji, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. European archives of psychiatry and clinical neuroscience. 2011. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics. 2011. Morag Ayelet, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response. Psychiatric genetics. 2011. Wu Gui-Sheng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clinical pharmacology and therapeutics. 2011. Ji Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 variation and citalopram response. Pharmacogenetics and genomics. 2011. Mrazek David A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. European psychiatry : the journal of the Association of European Psychiatrists. 2010. Benedetti F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and gender association with psychotic episodes on nortriptyline lower doses: patient cases. ISRN pharmaceutics. 2011. Piatkov Irina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. Journal of affective disorders. 2010. Gudayol-Ferré Esteve, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. Journal of psychopharmacology (Oxford, England). 2010. Umene-Nakano Wakako, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics. 2010. Lin Keh-Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neuroscience letters. 2010. Zou Yan-Feng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HTR2A is associated with SSRI response in Major Depressive Disorder in a Japanese cohort. Neuromolecular medicine. 2010. Kishi Taro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. The pharmacogenomics journal. 2010. Ji Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. Journal of child and adolescent psychopharmacology. 2010. Harris Elana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. International clinical psychopharmacology. 2010. Noro Magali, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. Journal of affective disorders. 2010. Serretti Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. Journal of affective disorders. 2010. Yevtushenko Olga O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Unschuld Paul G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. The pharmacogenomics journal. 2010. de Vos A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. The pharmacogenomics journal. 2010. Schenk P W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2010. Casamassima Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A genomewide association study of citalopram response in major depressive disorder. Biological psychiatry. 2010. Garriock Holly A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. European journal of pharmacology. 2010. Fudio Salvador, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. International clinical psychopharmacology. 2010. Dombrovski Alexandre Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. Journal of clinical pharmacology. 2010. Jin Yuyan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Horstmann Sonja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of Mu-Opioid Receptor Variants and Response to Citalopram Treatment in Major Depressive Disorder. The American journal of psychiatry. 2010. Garriock Holly A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. The American journal of psychiatry. 2010. Uher Rudolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2010. Domschke Katharina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010. Tsai Ming-Hsien, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology. 2010. Murata Yusuke, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biological & pharmaceutical bulletin. 2010. Katoh Yasuhiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clinical pharmacology and therapeutics. 2009. Oberlander T F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology. 2010. Zou Yan-Feng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical pharmacology and therapeutics. 2009. Pizzi C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. International clinical psychopharmacology. 2009. Serretti Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Human psychopharmacology. 2009. Yoshimura Reiji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Expression and association analyses of promoter variants of the neurogenic gene HES6, a candidate gene for mood disorder susceptibility and antidepressant response. Neuroscience letters. 2009. Glubb Dylan M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology. 2009. Min Wenjiao, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. European journal of clinical pharmacology. 2009. Saeki Yoshinori, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neuroscience research. 2009. Kishi Taro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLC6A4 variation and citalopram response. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2009. Mrazek D A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Archives of general psychiatry. 2009. Licinio Julio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological psychiatry. 2009. Perlis Roy H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose. Clinical pharmacology and therapeutics. 2009. Kumar V V P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug metabolism and disposition: the biological fate of chemicals. 2009. Rudberg I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. European journal of clinical pharmacology. 2009. Noehr-Jensen L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2009. Maron Eduard, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. International journal of psychiatry in clinical practice. 2009. Van Nieuwerburgh Filip C W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. Journal of affective disorders. 2009. Alexopoulos George S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009. Perroud Nader, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenetics and genomics. 2009. Laje Gonzalo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry research. 2009. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Moderation of antidepressant response by the serotonin transporter gene. The British journal of psychiatry : the journal of mental science. 2009. Huezo-Diaz Patricia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine. The pharmacogenomics journal. 2009. Glubb D M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology. 2009. Benedetti Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. The pharmacogenomics journal. 2009. Wilkie M J V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2009. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clinical pharmacokinetics. 2009. Lobo Evelyn D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenetics and genomics. 2009. Ruhé Henricus G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clinical pharmacokinetics. 2009. Ververs F F Tessa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. European journal of clinical pharmacology. 2008. Rudberg I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. Journal of thrombosis and haemostasis : JTH. 2008. Abdelmalik N, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2009. Hori Hikaru, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Therapeutic drug monitoring. 2008. Watanabe Junzo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Molecular psychiatry. 2008. Wong M-L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2008. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Therapeutic drug monitoring. 2008. Gex-Fabry Marianne, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. Journal of pain and symptom management. 2008. Forget Patrice, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genetic testing. 2008. Dogan Ozlem, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Molecular psychiatry. 2008. Schenk P W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenetics and genomics. 2008. Tzvetkov Mladen Vassilev, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biological psychiatry. 2008. Lekman Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphism and bleeding time during SSRI therapy. British journal of clinical pharmacology. 2008. Hougardy Dahlia M C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clinical pharmacology and therapeutics. 2008. Rudberg I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. European journal of clinical pharmacology. 2008. Ohlsson Rosenborg Staffan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. European journal of clinical pharmacology. 2008. Hermann M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?. Neuroscience letters. 2008. Baune B T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenetics and genomics. 2008. Tsai Shih-Jen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatric genetics. 2008. Crowley James J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. The pharmacogenomics journal. 2008. Tsai S-J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. British journal of clinical pharmacology. 2008. Bijl Monique J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucocorticoid receptor gene polymorphisms in premenopausal women with major depression. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme. 2008. Krishnamurthy P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. Journal of psychiatry & neuroscience : JPN. 2008. Lotrich Francis E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2008. Tanaka Misuzu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. British journal of clinical pharmacology. 2008. Halling Jónrit, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PloS one. 2008. Peters Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecules that mediate mood. The New England journal of medicine. 2007. Thase Michael E. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2008. Bozina Nada, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics in modern psychiatry. Psychiatria Danubina. 2007. Mihaljević-Peles Alma, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals. 2007. Shen Hongwu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of general psychiatry. 2007. Hu Xian-Zhang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Archives of general psychiatry. 2007. Perlis Roy H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. International clinical psychopharmacology. 2007. Smits Kim, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA : the journal of the American Medical Association. 2007. Bridge Jeffrey A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. Journal of affective disorders. 2007. Papiol Sergi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clinic proceedings. Mayo Clinic. 2007. McAlpine Donald E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. The American journal of psychiatry. 2007. Paddock Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neuroscience letters. 2007. Liu Zhongchun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans. International journal of clinical pharmacology and therapeutics. 2007. Kuhn U D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. Journal of sex & marital therapy. 2007. Zourková Alexandra, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS spectrums. 2006. Johnson Maria, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA : the journal of the American Medical Association. 2006. Kim Hyeran, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proceedings of the National Academy of Sciences of the United States of America. 2006. Wong Ma-Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Findling Robert L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Sequence-based CYP2D6 genotyping in the Korean population. Therapeutic drug monitoring. 2006. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American journal of human genetics. 2006. McMahon Francis J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British journal of clinical pharmacology. 2006. Feng Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic science international. 2006. Koski Anna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. International journal of geriatric psychiatry. 2006. Whyte Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of clinical pharmacy and therapeutics. 2006. Shams M E E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. Journal of clinical psychopharmacology. 2006. Yin Ophelia Q P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry. 2006. Stephan P L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Progress in neuro-psychopharmacology & biological psychiatry. 2006. Ueda Mikito, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depressive symptoms as first manifestation of posterior cortical atrophy. The American journal of psychiatry. 2006. Wolf Robert Christian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Therapeutic drug monitoring. 2006. Rudberg Ida, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. Journal of clinical psychopharmacology. 2006. Güzey Cüneyt, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Suzuki Yutaro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. The pharmacogenomics journal. 2006. Hong C-J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. The pharmacogenomics journal. 2006. Sugai T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic & clinical pharmacology & toxicology. 2005. Scordo Maria G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sequence analysis of the serotonin transporter and associations with antidepressant response. Biological psychiatry. 2005. Kraft Jeffrey B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International clinical psychopharmacology. 2005. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clinical chemistry. 2005. Steimer Werner, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature genetics. 2004. Binder Elisabeth B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Therapeutic drug monitoring. 2004. Laine Kari, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of general psychiatry. 2004. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clinic proceedings. Mayo Clinic. 2004. Sato Akinori, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. European journal of clinical pharmacology. 2004. Sawamura Kazushi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. Journal of Korean medical science. 2004. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clinical chemistry. 2004. Steimer Werner, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2004. Serretti Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology. 2004. Durham L Kathryn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Human psychopharmacology. 2004. Vandel P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clinical pharmacology and therapeutics. 2004. Rau Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. European journal of clinical pharmacology. 2004. Grasmäder Katja, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. The Journal of clinical psychiatry. 2004. Berle Jan Øystein, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. European journal of clinical pharmacology. 2004. LLerena Adrián, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. European journal of clinical pharmacology. 2004. Kawanishi Chiaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human psychopharmacology. 2004. Roberts Rebecca L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Therapeutic drug monitoring. 2003. Charlier Corinne, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological psychiatry. 2003. Perlis Roy H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of antidepressant medication intolerance. The American journal of psychiatry. 2003. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Therapeutic drug monitoring. 2003. Gerstenberg Gisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology. 2003. Gerstenberg Gisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. British journal of clinical pharmacology. 2003. Herrlin Karin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. Journal of clinical psychopharmacology. 2003. Arias Bárbara, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. General physiology and biophysics. 2003. Zourková A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. European journal of clinical pharmacology. 2003. Ohara Koichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. The Journal of pharmacology and experimental therapeutics. 2002. Yu Aiming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002. Takahashi Hitoshi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. Journal of clinical psychopharmacology. 2002. Solai LalithKumar K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. Journal of clinical psychopharmacology. 2002. Shimoda Kazutaka, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002. Lam Y W Francis, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human psychopharmacology. 2002. Stedman Catherine A M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Serotonin syndrome - 'potential' role of the CYP2D6 genetic polymorphism in Asians. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2002. Kaneda Yasuhiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in neuro-psychopharmacology & biological psychiatry. 2002. Yoshida Keizo, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. Journal of clinical psychopharmacology. 2001. Yokono A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular psychiatry. 2002. Yu Y W-Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. The pharmacogenomics journal. 2002. Roberts R L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. The pharmacogenomics journal. 2002. Di Bella D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The major fluvoxamine metabolite in urine is formed by CYP2D6. European journal of clinical pharmacology. 2001. Spigset O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2001. Murphy G M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clinical pharmacology and therapeutics. 2001. Laine K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological psychiatry. 2001. Zanardi R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A prospective study of 86 new patients with social anxiety disorder. Acta psychiatrica Scandinavica. 2001. Allgulander C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. Journal of clinical psychopharmacology. 2001. Eap C B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clinical pharmacology and therapeutics. 2001. Wang J H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neuroscience letters. 2001. Minov C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Enantioselective analysis of citalopram and metabolites in adolescents. Therapeutic drug monitoring. 2001. Carlsson B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2000. Pollock B G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clinical pharmacology and therapeutics. 2000. Yoon Y R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Venlafaxine serum levels and CYP2D6 genotype. Therapeutic drug monitoring. 2000. Veefkind A H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. Journal of clinical psychopharmacology. 2000. Morita S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of clinical psychopharmacology. 2000. Zanardi R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clinical pharmacology and therapeutics. 2000. Härtter S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000. Kim D K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. British journal of clinical pharmacology. 1999. Brynne N, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. Journal of clinical psychopharmacology. 1999. Ozdemir V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clinical pharmacology and therapeutics. 1999. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Paroxetine pharmacokinetics in depressed children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1999. Findling R L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. British journal of clinical pharmacology. 1999. Xu Z H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999. Lessard E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999. Fjordside L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular psychiatry. 1998. Smeraldi E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clinical pharmacology and therapeutics. 1998. Yue Q Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clinical pharmacology and therapeutics. 1998. Dalén P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Non-linear fluvoxamine disposition. British journal of clinical pharmacology. 1998. Spigset O, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. Pharmacopsychiatry. 1998. Baumann P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry and clinical neurosciences. 1997. Morinobu S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European journal of clinical pharmacology. 1997. Spigset O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. European journal of clinical pharmacology. 1997. Spina E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clinical pharmacology and therapeutics. 1996. Hamelin B A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clinical pharmacology and therapeutics. 1996. Carrillo J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. Journal of clinical psychopharmacology. 1996. Koyama E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical pharmacokinetics. 1996. Baumann P. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. Journal of clinical psychopharmacology. 1996. Baumann P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology. 1996. Dahl M L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. British journal of clinical pharmacology. 1995. Madsen H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. The Journal of pharmacology and experimental therapeutics. 1994. Koyama E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clinical pharmacology and therapeutics. 1994. Nielsen K K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Therapeutic drug monitoring. 1993. Sindrup S H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clinical pharmacology and therapeutics. 1993. Bluhm R E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993. Bertilsson L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. Journal of clinical psychopharmacology. 1992. Tacke U, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. 1992. Sindrup S H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. 1992. Sindrup S H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. European journal of clinical pharmacology. 1992. Nielsen K K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Nonlinear kinetics of imipramine in low and medium plasma level ranges. Therapeutic drug monitoring. 1990. Sindrup S H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Therapeutic drug monitoring. 1989. Balant-Gorgia A E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clinical pharmacology and therapeutics. 1988. Brøsen K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. European journal of clinical pharmacology. 1987. Balant-Gorgia A E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clinical pharmacology and therapeutics. 1986. Brøsen K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. International clinical psychopharmacology. 1986. Baumann P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. European journal of clinical pharmacology. 1986. Brøsen K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet. 1981. Bertilsson L, et al. PubMed